DaVita Inc. (DVA)
DaVita is a major American healthcare provider that specialises in life-saving kidney dialysis services for patients with chronic kidney failure.
Is DaVita Inc. a good stock for a UK beginner?
The honest version: DaVita is a major American healthcare provider that specialises in life-saving kidney dialysis services for patients with chronic kidney failure.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Successful expansion into new healthcare service areas
Significant disruption to the current healthcare funding model
What does DaVita Inc. do?
DaVita operates a vast network of clinics across the United States, helping people whose kidneys no longer function properly by filtering their blood. They make money primarily through the fees paid by insurance companies and government programmes for these essential, recurring treatments. Their profits turn on how they handle the rising costs of staffing and medical supplies while navigating changes in government healthcare funding.
On our factor screen it looks strongest on momentum and value, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 6% over the year
- !Carries a lot of debt - roughly 12.6x its equity
- ✓Strong return on shareholder money (ROE 81%)
- Value screens high (77/100)
- Momentum screens high (95/100)
- Provides an essential, life-sustaining medical service
- High return on equity indicates efficient management
- Strong recent earnings growth of 43.5%
- Income screens low (16/100)
- Changes to US healthcare legislation could impact revenue
- Shortage of specialised nursing staff
- Rising costs of medical equipment and supplies
What do DaVita Inc.'s numbers mean?
How much money does DaVita Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does DaVita Inc. pay a dividend?
No - DaVita Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does DaVita Inc. report earnings, and how did recent quarters go?
DaVita Inc. is next scheduled to report on about 2026-08-04 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-05 | $2.33 | $2.87 | Beat +23% |
| 2026-02-02 | $3.19 | $3.40 | Beat +7% |
| 2025-10-29 | $3.17 | $2.51 | Missed -21% |
| 2025-08-05 | $2.75 | $2.95 | Beat +7% |
| 2025-05-12 | $2.02 | $2.00 | In line |
| 2025-02-13 | $2.13 | $2.24 | Beat +5% |
Across the last 6 quarters here, DaVita Inc. came in ahead of what analysts expected 4 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for DaVita Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of DaVita Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Provides an essential, life-sustaining medical service
- High return on equity indicates efficient management
- Strong recent earnings growth of 43.5%
- No dividend payments for shareholders
- Low net profit margins leave little room for error
- Heavy reliance on government and insurance reimbursement rates
- Changes to US healthcare legislation could impact revenue
- Shortage of specialised nursing staff
- Rising costs of medical equipment and supplies
The write-up's own warning lights — if these start happening, the case above changes.
- A major shift in how the US government funds dialysis treatments
- A sustained decline in the number of patients requiring dialysis
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.